Hartil

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hartil

What is Hartil?

Hartil is a pharmaceutical medication belonging to the class of drugs known as ACE inhibitors (Angiotensin-Converting Enzyme inhibitors). The active substance in this medication is ramipril. It is primarily utilized in cardiovascular medicine to manage conditions affecting the heart and blood vessels.

How it Works

The medication functions by interfering with the body's production of a specific substance that causes blood vessels to tighten. By inhibiting this process, the medication helps the blood vessels to relax and widen. This action facilitates a more efficient flow of blood throughout the body and reduces the workload placed on the heart muscle.

Primary Therapeutic Uses

Hartil is commonly prescribed for several cardiovascular purposes:

  • Blood Pressure Management: It is used to lower high blood pressure (hypertension). Maintaining blood pressure within a standard range is a key factor in long-term cardiovascular health.
  • Heart Failure Support: It may be used in the management of heart failure, a condition where the heart does not pump blood as effectively as it should.
  • Post-Cardiac Events: The medication is often utilized following a myocardial infarction (heart attack) to improve survival outcomes and reduce the strain on the heart during recovery.
  • Kidney Protection: In certain patients, particularly those with diabetes or specific renal conditions, it may be used to help protect kidney function or delay the progression of kidney disease.
  • Risk Reduction: It is sometimes indicated for individuals at high risk of significant cardiovascular events, such as strokes or heart attacks, due to existing vascular disease or multiple risk factors.

General Characteristics

As a systemic treatment, the medication is absorbed into the bloodstream to provide continuous regulation of the vascular system. It is designed for long-term management of chronic conditions rather than the immediate relief of acute symptoms. Treatment is typically monitored by healthcare professionals to ensure the medication is achieving the desired physiological effects based on the individual's specific health profile.

What side effects are possible with Hartil?

Possible Side Effects and Safety Information

This section describes the safety characteristics and officially documented adverse reactions of Hartil (Ramipril), classified by government regulatory authorities.

Adverse Reaction Scope

The safety profile is structured by System-Organ Class (SOC) and Frequency of occurrence, consistent with regulatory guidelines.

Classification Examples of Reactions Listed in Official Documents
Common (1% to 10%) Headache, dizziness, non-productive tickling cough, fatigue, gastrointestinal upset, and increased blood potassium (hyperkalemia).
Uncommon (0.1% to 1%) Vertigo, paraesthesia, sleep disorders, and temporary erectile impotence.
Rare (less than 0.1%) Confusional states and cholestatic jaundice (yellowing of the skin/eyes).
Not Known Angioedema (swelling of the face, tongue, or larynx), acute hepatic failure, and severe blood disorders (e.g., neutropenia).

Serious Adverse Reactions and Safety Constraints

Serious adverse reactions that are officially documented include Angioedema, which is rapid swelling that can obstruct the airway, and the possibility of progressing to Fulminant Hepatic Failure. The label notes that hypotension (low blood pressure) is more common following the initiation of therapy or during periods of dose escalation.

Specific population constraints are: the medication is contraindicated during the second and third trimesters of pregnancy due to risk of fetal injury or death. Monitoring is necessary for individuals with pre-existing renal or hepatic impairment, as drug levels may be affected. The use is also restricted in patients with a history of Angioedema related to any ACE inhibitor.

Overdose and Emergency Response

The official regulatory documentation for Hartil (Ramipril) strictly defines the manifestations and required responses in the event of an overdose. The primary documented clinical manifestation is profound hypotension (severely low blood pressure), which is an exaggerated extension of the drug’s intended effect. Symptoms directly attributable to this may include light-headedness, confusion, and potential loss of consciousness (syncope).

Immediate action is mandatory for severe presentations. Regulatory guidance states that individuals must seek emergency medical attention or contact emergency services immediately if the patient faints and cannot be woken up, or becomes suddenly very dizzy or confused.

Serious, life-threatening outcomes documented in the official profile include acute renal failure and the potential for a severe increase in blood potassium (hyperkalemia). Furthermore, a patient experiencing hypovolemia (fluid deficit due to severe sweating or diarrhea) may be at increased risk of severe hypotensive effects.

Management is strictly symptomatic and supportive. As no specific antidote is known, care focuses on correcting the physiological effects, such as the intravenous infusion of saline solution to manage hypotension. Symptomatic patients require extended hospital monitoring, typically for at least 24 hours, with critical monitoring of vital signs and laboratory measures like BUN and serum creatinine.

Therapeutic Uses of Hartil

What Hartil Treats: Main Uses and Benefits

Hartil is generally used for managing conditions characterized by periods of heightened symptoms related to systemic imbalance. This medication can assist with maintaining functional stability and is applied in clinical settings that involve acute or unstable symptom patterns.

Hartil is commonly used to help with easing distress across four primary clinical situations: chronic management of high blood pressure, reducing the risk of major cardiovascular events (like stroke and heart attack) in high-risk individuals, supporting heart function in stable patients after a heart attack, and protecting against diabetic kidney disease (nephropathy).

“Its application in this specific context is relevant for easing symptoms that create noticeable physiological strain and supports general well-being during symptomatic phases.”

In these contexts, the medication helps address symptom clusters that may become intense or disruptive, which supports the patient during difficult episodes by easing distress. This supportive relief may assist with managing symptoms that interfere with daily comfort.


Quick Fact: Support for Systemic Imbalance

Property Description
Primary Focus Managing symptoms related to systemic imbalance
Core Benefit Assists with maintaining functional stability
Use Scenario Long-term management of chronic conditions
Goal Supports general well-being during symptomatic phases

Regulatory References

  1. NIH DailyMed official drug label

Eligibility and Restrictions for Use

Official Population Eligibility for Hartil (Ramipril)

The ability to use Hartil is strictly determined by official regulatory documents, which establish specific populations that are approved, restricted, or entirely prohibited from treatment.

Category Regulatory Eligibility Status
Contraindicated Populations Individuals with a history of angioedema (swelling related to any ACE inhibitor) or known hypersensitivity to Ramipril. Women in the second and third trimesters of pregnancy. Patients with bilateral renal artery stenosis or stenosis in a single functioning kidney.
Dual Therapy Restriction Contraindicated for patients with diabetes or moderate-to-severe renal impairment who are also taking aliskiren-containing products. Use is forbidden within 36 hours of taking sacubitril/valsartan.
Age-Related Rules Approved for use in adults (generally ge 18 years). Use in children and adolescents ( age < 18 years) is not established and not generally recommended.
Physiological Status Use is not recommended during the first trimester of pregnancy or for nursing mothers.
Conditional Use Patients with impaired renal or hepatic function may be eligible but require close monitoring and often an adjustment to the initial dose, as detailed in the official prescribing information.

Regulatory documents use classifications such as Contraindicated for absolute prohibitions and Not Recommended or Use Not Established for populations lacking sufficient safety data, clearly defining the strict boundaries for appropriate use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Hartil's official interaction profile is structured around prohibitions on dual blockade of the Renin-Angiotensin System (RAS) and pharmacodynamic conflicts. Co-administration with Neprilysin (NEP) Inhibitors (e.g., Sacubitril/Valsartan) is formally contraindicated, necessitating a mandatory 36-hour washout period when transitioning between these medications. Further prohibitions include the contraindication of Hartil with Aliskiren in patients with Diabetes Mellitus or moderate to severe Renal Impairment. The combination with Angiotensin II Receptor Antagonists (ARBs) is also contraindicated in patients with Diabetic Nephropathy.

Interactions with agents influencing blood pressure or electrolytes are common. The simultaneous use of Diuretics or Other Antihypertensive Agents may lead to additive effects, resulting in excessive hypotension. Conversely, co-administration with Potassium-Sparing Diuretics, Potassium Supplements, or Heparin increases the risk of Hyperkalemia.

Kinetic interactions are formally documented for specific substances. Ramipril reduces the renal clearance of Lithium, causing a significant increase in serum Lithium levels. The combination with Non-Steroidal Anti-Inflammatory Agents (NSAIDs) may both reduce the antihypertensive effect and increase the risk of renal function deterioration. Patients with Hepatic Impairment may exhibit elevated plasma Ramipril (parent drug) concentrations due to reduced conversion to the active metabolite.

Mechanism of Action

Hartil is a prodrug that undergoes hepatic and renal de-esterification to form its active metabolite, ramiprilat. Ramiprilat functions as a competitive inhibitor of Angiotensin-Converting Enzyme (ACE), also known as kininase II, which is a key component of the Renin-Angiotensin-Aldosterone System (RAAS).

The molecular target, ACE, is an enzyme responsible for converting the decapeptide angiotensin I to the potent vasoconstrictor, angiotensin II. Inhibition of ACE by ramiprilat consequently suppresses the formation of angiotensin II. The reduction in circulating and tissue-localized angiotensin II leads to decreased activation of the G-protein coupled Angiotensin II type 1 receptors (AT1R) on vascular smooth muscle cells and in the adrenal cortex.

Intracellularly, decreased AT1R signaling results in reduced Gq coupling and diminished activation of downstream pathways like inositol triphosphate (IP3). System-level physiological consequences include arteriolar smooth muscle relaxation, decreased total peripheral resistance, and reduced aldosterone secretion, leading to lessened renal tubular sodium and water reabsorption. Additionally, ACE inhibition impedes the degradation of bradykinin, a vasodilator peptide, which may further contribute to systemic vasodilation.

Dosage and Administration Information

How to Use Hartil

The usage of Hartil (Ramipril) is dictated by established protocols detailing the correct route, dosing schedule, and administration method. Hartil is an oral medication, available in strengths such as 1.25 mg, 2.5 mg, 5 mg, and 10 mg capsules or tablets.


Administration and Dosing Schedule

The medicine is designed for once-daily use in most situations, although some higher-dose regimens or specific treatment goals may require divided doses taken twice per day. It can be taken with or without food as the timing relative to meals does not significantly affect its absorption.

Treatment typically begins with a low initial dose, such as 2.5 mg once daily for high blood pressure management. This amount is gradually adjusted, or titrated, over several weeks to reach a defined maintenance range. The maximum recommended daily dose for hypertension can be up to 20 mg in some regions.


Special Administration Conditions

Ramipril capsules or tablets must be swallowed whole with liquid. If swallowing a capsule is difficult, the contents may be opened and sprinkled onto a small amount of applesauce or mixed with water or apple juice; the entire mixture must be consumed immediately after preparation.

For individuals with reduced kidney or liver function, common clinical protocols require a lower starting dose (e.g., 1.25 mg once daily) and a restricted maximum daily amount, confirming that usage patterns depend on a patient's physiological state. If a dose is missed, standard procedures advise the patient to skip the missed dose and resume the schedule at the next designated time, without taking two doses simultaneously.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Focus

Studies have investigated the medication for the treatment of pain and inflammation. Research examined the medication's effect on various biomarkers in trial participants.


Clinical Trials in Osteoarthritis

Studies have investigated the medication in populations with moderate to severe osteoarthritis.

  • Efficacy in Joint Pain: One major trial reported on the change in joint pain compared to placebo over a six-month period. Findings were mixed when comparing the drug to a non-selective NSAID reference group.
  • Functionality and Mobility: Several smaller studies examined whether the medication was associated with changes in patient-reported physical function scores (e.g., WOMAC scale). Evidence remains limited on the effect on long-term mobility.
  • Dosing: Study protocols described the use of the lowest possible dose in trials. The overall dosing schedule in trials included twice-daily periods.

Evaluation in Combination Therapy

Research has evaluated whether the use of the drug combined with paracetamol is associated with a different response compared to paracetamol alone. Some trial sites explored the possibility of a dose-sparing effect when the drugs were co-administered.


Safety Profile Overview

Trial reports included information on gastrointestinal events. These events included ulcers.

  • Cardiovascular Safety: The clinical trial protocols accounted for participants who had existing heart conditions. The largest safety study examined the rate of major adverse cardiovascular events (MACE) in participants taking the drug compared to those taking placebo.
  • Liver Function: Pre-clinical data and early-stage trials evaluated whether the drug was associated with changes in liver enzymes (ALT and AST).

Pharmacokinetics and Absorption

The current formulation was used in the studies. Research has investigated the time to maximum concentration in the blood. Pharmacokinetic studies reported on the half-life of the drug.


Summary of Research Focus

Research has explored whether the medication is associated with changes in chronic pain. The overall body of evidence was reviewed to understand the medication's studied effects and safety profile.

Frequently Asked Questions (FAQ)

Common questions about Hartil (FAQ)


Q: Is Hartil the same as [Name of a similar common drug]?

A: Official documents describe Hartil's active ingredient, Ramipril, as belonging to the Angiotensin-Converting Enzyme (ACE) Inhibitor class. Medicines within this class share a similar primary function: to reduce blood pressure and ease the workload on the heart. However, each specific drug has its own unique regulatory profile and may vary in details.


Q: How quickly does Hartil start working after I take the first dose?

A: According to the official product information, the active form of Hartil, known as Ramiprilat, typically reaches its peak intended effect in the body between 3 and 6 hours after the dose is taken. This marks the time when the drug's action is most pronounced.


Q: What is the average time Hartil stays active in the body?

A: The active substance in Hartil has an elimination half-life, which is the time it takes for half the drug to be removed from the body. Official sources describe this as being between 13 and 17 hours in most cases. This duration is consistent with the general recommendation for once-daily use.


Q: Is it true that Hartil can cause a dry cough?

A: Yes, official documents list a non-productive, tickling cough as a common side effect, meaning it is reported in 1% to 10% of patients. This type of cough is often associated with the way ACE inhibitor medications work within the body's natural systems. It generally does not respond to common cough medicines.


Q: Can I take Hartil if I also take a common pain reliever like ibuprofen?

A: Official warnings state that taking Hartil with Non-Steroidal Anti-Inflammatory Agents (NSAIDs), which includes ibuprofen, is associated with a documented interaction. This combination may reduce the intended blood-pressure-lowering effect of Hartil. Additionally, official information indicates an increased potential for changes in kidney function.


Q: What happens if I miss taking Hartil for a day?

A: If a dose is missed, official instructions advise to skip the missed dose completely and return to the normal schedule at the next designated time. Official instructions advise against taking two doses at the same time to compensate for a missed dose.


Q: Can people over 65 years old generally use Hartil?

A: Hartil is generally approved for use in adults. Official guidance indicates that a lower initial dose may be required for elderly patients, as specified in regulatory information for patients who may have reduced kidney or liver function.


Q: Is Hartil suitable for use in children?

A: Official documents state that the safety and effectiveness of Hartil have not been established in children and adolescents, meaning those under 18 years of age. Therefore, its use in this age group is not generally recommended.


Q: Is it okay to take Hartil in the morning or the evening?

A: Hartil is designed for once-daily use, and it is recommended to take it at approximately the same time each day for consistency. The precise timing for administration should be determined by the prescriber.


Q: Can Hartil be crushed or split?

A: Tablets or capsules must generally be swallowed whole. If a capsule is prescribed and swallowing is difficult, the contents may be opened and mixed with a small amount of applesauce or liquid and consumed immediately. Official instructions do not include guidance for splitting the tablet form.


Q: Does Hartil interact with alcohol?

A: Alcohol (ethanol) may have an additive effect with Hartil in lowering blood pressure. Official warnings state that this combination may increase the potential for symptoms such as dizziness, lightheadedness, or fainting, especially when treatment begins.


Q: Are there any specific vitamins or supplements that should not be taken with Hartil?

A: Yes, official warnings state that supplements containing potassium, which includes salt substitutes that use potassium chloride, are listed as substances to be avoided when using Hartil. This is because the medication can cause the body to retain potassium, which may lead to elevated levels in the blood.


Q: Can a person stop taking Hartil suddenly if they feel better?

A: Official documents state that sudden discontinuation or alteration of the dosage is not advised. This is consistent with regulatory statements for medications used in the long-term management of cardiovascular conditions.


Q: Is Hartil considered a blood pressure medicine?

A: Yes, Hartil is formally classified as an Angiotensin-Converting Enzyme (ACE) Inhibitor. This is a type of prescription medication commonly used for the management of high blood pressure, also known as hypertension.


Q: What are the concerns about taking Hartil during pregnancy?

A: Official warnings state that using Hartil in the second and third trimesters of pregnancy is strictly contraindicated. This is due to the risk of fetal injury or death, particularly the risk of damage to the baby's developing kidneys.


Q: What type of monitoring is often suggested when starting Hartil?

A: Official documents recommend regular monitoring, including blood tests, particularly when starting treatment or when the dose is increased. This monitoring is typically done to check potassium levels and assess how well the kidneys are functioning.


Q: Does taking Hartil affect kidney function over time?

A: Official product information requires monitoring because of the potential for impairment of renal function, particularly in individuals with certain pre-existing conditions. Close monitoring helps ensure the drug is tolerated well.


Q: Is it normal for my heart rate to change slightly after starting Hartil?

A: Clinical studies generally indicate that the drug's mechanism is designed to lower blood pressure without directly changing the heart rate. However, rapid changes in blood pressure, especially when initiating treatment, can sometimes cause a temporary effect on heart rate.


Q: Does Hartil affect cholesterol levels?

A: Research evidence indicates that clinical doses of Hartil's active ingredient likely do not directly modify cholesterol levels. However, some studies have been associated with reduced levels of LDL (low-density lipoprotein) and HDL (high-density lipoprotein) cholesterol.


Q: Can Hartil cause dizziness when standing up?

A: Yes, dizziness or lightheadedness are common side effects, especially when treatment is started or the dose is increased. This can be more noticeable when changing body positions, such as standing up quickly.


Q: Do many people experience a metallic taste when starting Hartil?

A: Official documents note that Hartil may alter a person's sense of taste. While taste disturbances are not classified as a common side effect, they are sometimes reported.


Q: Does the color of the Hartil pill mean anything?

A: Yes, the color, shape, and markings of the tablet or capsule are used by the manufacturer to help identify the specific strength and dose of the Hartil medication. It is important to confirm that the color matches the expected strength.


Q: What if I have an allergic reaction to Hartil?

A: Signs of a severe allergic reaction (such as rapid swelling of the face, tongue, or throat, or sudden confusion or fainting) are officially documented as serious adverse events.


Q: Does Hartil interact with cold or flu medications?

A: Hartil can interact with various non-prescription medications, including some cold and flu treatments which may contain ingredients like NSAIDs or decongestants. Official guidance recommends checking with a healthcare professional before combining Hartil with any other over-the-counter medicine.


Q: How common is the side effect of feeling lightheaded with Hartil?

A: Feeling lightheaded is associated with the general side effect of dizziness, which is documented in official sources as a Common occurrence. This means it has been reported in 1% to 10% of patients.


Q: Can Hartil cause changes in blood sugar levels?

A: Official safety information indicates that Hartil can potentially lower blood sugar levels. Official information indicates that close monitoring of blood sugar may be necessary for patients with diabetes, particularly when treatment begins.


Q: Is there a maximum time someone can take Hartil?

A: Hartil is typically prescribed for the long-term, chronic management of high blood pressure and other cardiovascular conditions. There is no specific maximum time limit stated in official documents for its continuous use.


Q: Does Hartil affect the ability to drive or operate machinery?

A: Due to the risk of side effects like dizziness, lightheadedness, or tiredness, official warnings state that activities requiring concentration, such as driving or operating machinery, may need to be approached with caution.


Q: Are there certain foods or drinks that should be limited while on Hartil?

A: Because Hartil can cause the body to retain potassium, which can lead to elevated potassium levels in the blood, certain foods and drinks that are high in potassium are noted as substances that may require limitation.


Q: What is the difference between Hartil and its metabolites in the body?

A: Hartil is classified as a pro-drug, which means the compound (Ramipril) is inactive when ingested. It requires metabolic conversion, primarily in the liver, into its highly active form, Ramiprilat, to produce the intended therapeutic effect on the body.


Q: Does Hartil have warnings about sun exposure?

A: Official safety information indicates that Hartil can make the skin more sensitive to sunlight (UV rays), which may increase the risk of sunburn. Protective measures against sun exposure may be considered while using this medication.

How should Hartil be stored and disposed of?

How to Store and Dispose of Hartil?

The official storage conditions for Hartil (ramipril) are defined by regulatory documents to maintain product integrity.


Storage Requirements

  • Temperature: Store at Controlled Room Temperature, specifically between 20 C and 25 C (68 F to 77 F). The medicine must be protected from freezing and excess heat.
  • Protection: The container must be kept tightly closed and away from excess moisture and direct light.
  • Child Safety: It is mandatory to keep all medication out of the sight and reach of children.

Disposal

Do not flush unused or expired Hartil down the toilet unless explicitly instructed by a drug take-back program. Disposal must follow local regulations for pharmaceutical waste. Any medication no longer needed should be discarded promptly.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hartil found in:

A-Z Index: